Aspirin Resistance and Promoting Blood Circulation and Removing Blood Stasis: Current Situation and Prospectives
Table 5
Analysis of platelet aggregation rate induced by ADP.
Trials
MD (95% CI)
value
Chinese formula versus anti-platelet-aggregation drugs
Tong xin luo capsule versus clopidogrel
1
13.32 [7.68, 18.96]
<0.00001
Zhilong huoxue capsule versus aspirin
1
−5.50 [−10.49, −0.51]
0.03
Di’ao xinxuekang capsule versus aspirin
1
−5.50 [−10.49, −0.51]
0.03
Meta-analysis
3
0.70 [−11.07, 12.48]
0.91
Chinese formula plus anti-platelet-aggregation drugs versus anti-platelet-aggregation drugs
Composite salvia dropping pill plus aspirin versus aspirin
1
−13.92 [−19.58, −8.26]
<0.00001
Huo xue capsule plus aspirin versus aspirin
1
−40.97 [−49.64, −32.30]
<0.00001
Tong xin luo capsule plus aspirin versus aspirin
1
−2.51 [−4.46, −0.56]
0.01
Xinnao shutong capsule plus aspirin versus aspirin
1
−23.26 [−26.11, −20.41]
<0.00001
Xuefu zhuyu decoction plus aspirin versus aspirin
1
−16.82 [−22.12, −11.52]
<0.00001
Ginkgo biloba extract plus aspirin versus aspirin
1
−2.87 [−7.00, 1.26]
0.17
Meta-analysis
5
−17.61 [−19.56, −15.65]
<0.00001
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.
